Two-drug combination for advanced kidney cancer
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (envafolimab and axitinib) as the first treatment for advanced kidney cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced kidney cancer (clear cell type) that cannot be removed with surgery or has spread to other parts of the body.
- You have not received any previous drug treatment for your kidney cancer.
- You are physically active and able to take care of yourself (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and blood clotting labs are within acceptable ranges.
- Expected survival is at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This study tests a new combination of medicines for people with advanced clear cell kidney cancer that has gotten worse after first treatment. The combination includes two immunotherapy drugs (iparomlimab and tuvonralimab) plus one of two targeted therapy pills (lenvatinib or axitinib). The goal is to see if this approach can help control the cancer.
This trial tests a new combination of three drugs (ipilimumab, sintilimab, and lenvatinib) as the first treatment for a specific type of advanced kidney cancer caused by a TFE3 gene change. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Advanced Renal Cell Carcinoma (aRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.